3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Melphalan
5
Dexamethasone
4
Peripheral Blood Stem Cell Transplantation
3
Filgrastim
3
isatuximab
2
Cyclophosphamide
2
Calcium Dobesilate
2
pomalidomide
1
liposomal amphotericin B
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
belantamab mafodotin
1
auricularum
1
Watchful Waiting
1
Thalidomide
1
Stem Cell Transplantation
1
Specimen Handling
1
Moxifloxacin
1
Morphine
1
Magnetic Resonance Spectroscopy
1
Interferon-alpha
1
In Situ Hybridization, Fluorescence
1
Dextromethorphan
1
Cytogenetic Analysis
1
Ciprofloxacin
1
Caspofungin
1
Bortezomib
1
Biopsy
1
Amoxicillin-Potassium Clavulanate Combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Immunoglobulin Light-chain Amyloidosis
×
belantamab mafodotin
×
Clear all
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled